Pembrolizumab: living up to expectations
- PMID: 31582369
- DOI: 10.1182/blood.2019002417
Pembrolizumab: living up to expectations
Conflict of interest statement
Conflict-of-interest disclosure: The author received research funding (to his institution for clinical trials) from Bristol Myers Squibb, Merck, Seattle Genetics, Regeneron, Trillium, Pfizer, and Affimed.
Comment on
-
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13. Blood. 2019. PMID: 31409671 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

